Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $607

Vertex Pharmaceuticals Incorporated -1.84%

Vertex Pharmaceuticals Incorporated

VRTX

469.34

-1.84%

Barclays analyst Eliana Merle maintains Vertex Pharmaceuticals (NASDAQ: VRTX) with a Overweight and raises the price target from $606 to $607.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via